Bill Text: AZ SB1702 | 2023 | Fifty-sixth Legislature 1st Regular | Introduced
Bill Title: Gender transition; prohibitions; hormone therapies
Spectrum: Partisan Bill (Republican 3-0)
Status: (Introduced - Dead) 2023-02-02 - Senate read second time [SB1702 Detail]
Download: Arizona-2023-SB1702-Introduced.html
|
REFERENCE TITLE: gender transition; prohibitions; hormone therapies |
|
State of Arizona Senate Fifty-sixth Legislature First Regular Session 2023
|
|
SB 1702 |
|
|
|
Introduced by Senator Wadsack: Representatives Jones, McGarr
|
An Act
amending section 32-3230, Arizona Revised Statutes; relating to health professionals.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Section 32-3230, Arizona Revised Statutes, is amended to read:
32-3230. Prohibition of permanent gender reassignment surgery for minors; prohibition on referring for or providing hormone therapy for minors; definitions
A. A physician may not provide irreversible PERMANENT gender reassignment surgery to any individual who is under eighteen years of age. A health professional may not make a referral for or provide cross-sex hormones or puberty-blocking drugs to any individual who is under eighteen years of age.
B. A physician may provide any of the following to an individual who is under eighteen years of age:
1. Services to an individual born with a medically verifiable disorder of sex development, including an individual with external biological sex characteristics that are irresolvably ambiguous, such as being born with forty-six XX chromosomes with virilization or forty-six XY chromosomes with undervirilization or having both ovarian and testicular tissue.
2. Services provided when a physician has otherwise diagnosed a disorder of sexual development and has determined through genetic or biochemical testing that the individual does not have normal sex chromosome structure, sex steroid hormone production or sex steroid hormone action.
3. The treatment of any infection, injury, disease or disorder that has been caused by or exacerbated by the performance of gender transition procedures, whether or not the gender transition procedure was performed in accordance with state and federal law.
4. Any procedure undertaken because the individual suffers from a physical disorder, physical injury or physical illness that would, as certified by a physician, place the individual in imminent danger of death or impairment of major bodily function unless surgery is performed.
C. For the purposes of this section:
1. "Biological sex" means the biological indication of male and female in the context of reproductive potential or capacity, such as sex chromosomes, naturally occurring sex hormones, gonads and nonambiguous internal and external genitalia present at birth, without regard to an individual's psychological, chosen or subjective experience of gender.
2. "Cross-sex hormones" means either of the following:
(a) Testosterone or other androgens given to biological females in amounts that are larger or more potent than would normally occur naturally in healthy biological sex females.
(b) Estrogen given to biological males in amounts that are larger or more potent than would normally occur naturally in healthy biological sex males.
2. 3. "Gender" means the psychological, behavioral, social and cultural aspects of being male or female.
3. 4. "Gender transition" means the process in which a person goes from identifying with and living as a gender that corresponds to the person's biological sex to identifying with and living as a gender different from the person's biological sex and may involve social, legal or physical changes.
4. 5. "Irreversible PERMANENT gender reassignment surgery" means a medical procedure performed for the purpose of assisting an individual with a gender transition, including any of the following:
(a) Penectomy, orchiectomy, vaginoplasty, clitoroplasty or vulvoplasty for biologically male patients or hysterectomy or ovariectomy for biologically female patients.
(b) Metoidioplasty, phalloplasty, vaginectomy, scrotoplasty or implantation of erection or testicular prostheses for biologically female patients.
(c) Augmentation mammoplasty for biologically male patients and subcutaneous mastectomy for female patients.
5. 6. "Physician" means a person who is licensed pursuant to chapter 13 or 17 of this title.
7. "Puberty-blocking drugs" means either of the following when used to delay or suppress pubertal development in children for the purpose of assisting an individual with a gender transition:
(a) Gonadotropin-releasing hormone analogues or other synthetic drugs used in biological sex males to stop luteinizing hormone secretion and testosterone secretion.
(b) Synthetic drugs used in biological sex females to stop the production of estrogens and progesterone.
Sec. 2. Effective date; purpose
A. This act is effective from and after March 31, 2024.
B. The effective date of this act is delayed so that minors in this state who are currently using puberty-blocking drugs or cross-sex hormones have time for appropriate medication tapering and discontinuation under the care of the minor's physician or other health professional.
